Search Results - "MULFORD, D."

Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy by METZ, D. C., VAKILY, M., DIXIT, T., MULFORD, D.

“…Summary Background  Proton pump inhibitors (PPIs) provide the most effective pharmacotherapy for treating acid‐related disorders. However, PPIs do not…”
Get full text

Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor – evidence for dosing flexibility by LEE, R. D., VAKILY, M., MULFORD, D., WU, J., ATKINSON, S. N.

“…Summary Background  Dexlansoprazole MR is a proton pump inhibitor with a Dual Delayed Release (DDR) formulation designed to prolong the dexlansoprazole plasma…”
Get full text

The effect of time‐of‐day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor by LEE, R. D., MULFORD, D., WU, J., ATKINSON, S. N.

“…Aliment Pharmacol Ther 31, 1001–1011 Summary Background  Dexlansoprazole MR is a Dual Delayed Release proton pump inhibitor formulated to extend the duration…”
Get full text

Febuxostat (TMX-67), a Novel, Non-Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers by Becker, M. A., Kisicki, J., Khosravan, R., Wu, J., Mulford, D., Hunt, B., MacDonald, P., Joseph-Ridge, N.

“…In order to evaluate the safety, pharmacological properties, and urate-lowering efficacy of febuxostat, a non-purine, selective inhibitor of xanthine oxidase,…”
Get full text

Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects by Freston, J. W., Chiu, Y.‐L., Mulford, D. J., Ballard II, E. D.

“…Summary Background : Many individuals with acid‐related gastrointestinal disorders have difficulty in swallowing oral agents. Aim : To compare the…”
Get full text

Oxidative metabolism of clarithromycin in the presence of human liver microsomes : Major role for the cytochrome P4503A (CYP3A) subfamily by RODRIGUES, A. D, ROBERTS, E. M, MULFORD, D. J, YAO, Y, OUELLET, D

“…In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) protein(s) involved in the oxidative metabolism of [14C]clarithromycin (CLAR) in…”
Get full text

Who Should Receive Retrievable Inferior Vena Cava Filters? by Rizzo, A, Aldaghlas, T, Okasun, S, Sakran, J, Kimberly, H, Robinson, L, Kim, C, King, E, Mulford, D, Drooz, A, Fakhry, S

Get full text

Copy number variations and loss of heterozygosity identified in myelodysplastic syndrome by Hu, X, Iqbal, A, Ahmed, A, Raca, G, Xu, X, Wolff, D.J, Burack, R, Mulford, D, Li, M.M

Get full text

Transversalidad y currículo: Estrategias de aprendizaje en Instituciones de Educación Superior colombianas by Mulford, Marelys D, de Plata, Dalia Isbelia Plata, Gómez, Fredy Mestre, Yarzagaray, Oscar Torres

“…El desarrollo de la formación actual está orientado a ofrecer educación de calidad con recursos limitados. Esta investigación, ha puesto en circunstancias…”
Get full text

Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects by Khosravan, R., Erdman, K., Vernillet, L., Wu, J. T., Joseph‐Ridge, N., Umeda, S., Mulford, D.

“…Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients with gout…”
Get full text

In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices by Rodrigues, A D, Mulford, D J, Lee, R D, Surber, B W, Kukulka, M J, Ferrero, J L, Thomas, S B, Shet, M S, Estabrook, R W

“…The metabolism of terfenadine was studied with a cDNA-expressed/purified recombinant fusion protein containing human liver microsomal cytochrome P4503A4…”
Get more information

Benign versus malignant papillary neoplasms of the breast. Diagnostic clues in fine needle aspiration cytology by Dawson, A E, Mulford, D K

“…Benign and malignant papillary lesions of the breast can be difficult to distinguish in both cytologic and histologic preparations. To determine the cytologic…”
Get more information

Breast fine-needle aspiration. A comparison of thin-layer and conventional preparation by Perez-Reyes, N, Mulford, D K, Rutkowski, M A, Logan-Young, W, Dawson, A E

“…Two hundred forty-two breast fine-needle aspirates prepared by the Cytyc ThinPrep Processor were compared with aspirates prepared by the conventional smear…”
Get more information

Atypia in fine needle aspiration cytology of nonpalpable and palpable mammographically detected breast lesions by Mulford, D K, Dawson, A E

“…Widespread use of fine needle aspiration (FNA) in conjunction with mammography may lead to increased atypical or suspicious cytologic diagnoses. To assess the…”
Get more information

Fine needle aspiration of mucinous (colloid) breast carcinoma : Nuclear grading and mammographic and cytologic findings by DAWSON, A. E, MULFORD, D. K

“…The clinical, mammographic and low grade cytologic features of mucinous carcinoma can make it difficult to diagnose by fine needle aspiration (FNA). Fine…”
Get full text

Breast carcinoma detection in women age 35 years and younger: Mammography and diagnosis by fine-needle aspiration cytology by DAWSON, A. E, MULFORD, D. K, TAYLOR, A. S, LOGAN-YOUNG, W

“…Delays in breast carcinoma diagnosis may occur in young women due to a low index of suspicion. Fine-needle aspiration (FNA) is an ideal method for evaluating…”
Get full text

Stereoselective pharmacokinetics of pazinaclone, a new non‐benzodiazepine anxiolytic, and its active metabolite in healthy subjects by HUSSEIN, Z., MULFORD, D. J., BOPP, B. A., GRANNEMAN, G. R.

“…1 Serum and urine concentrations of enantiomers of pazinaclone (DN‐2327) and an active metabolite MII, were measured after single and twice daily oral doses of…”
Get full text

The cytopathology of proliferative breast disease. Comparison with features of ductal carcinoma in situ by Dawson, A E, Mulford, D K, Sheils, L A

“…Epithelial hyperplasia, a component of proliferative breast disease (PBD), is a known risk factor for the development of breast carcinoma. To determine if…”
Get more information

Aspiration cytology of tubular carcinoma. Diagnostic features with mammographic correlation by Dawson, A E, Logan-Young, W, Mulford, D K

“…The detection of early, well-differentiated breast carcinoma is increasing because of mammographic screening. Because fine-needle aspiration cytology is often…”
Get more information

Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function by WONG, S. L, MENACHERRY, S, MULFORD, D, SCHMITZ, P. J, LOCKE, C, GRANNEMAN, G. R

“…To study the effect of renal impairment on the pharmacokinetics of sertindole. A single 4 mg oral dose of sertindole was given to normal subjects (n = 6) and…”
Get full text